BioSpace News Archive

QIAGEN announced the release of its Sustainability Report 2022, emphasizing its unwavering focus on driving positive change for society through its goals for Environment, Social and Governance metrics.

Praxis Precision Medicines, Inc. announced that it will host a R&D Day on Monday, October 2, at 9:00 a.m. EDT, virtually and in person in New York City.

Takeda announced that the U.S. Food and Drug Administration has approved a subcutaneous administration of ENTYVIO® for maintenance therapy in adults with moderately to severely active ulcerative colitis after induction therapy with ENTYVIO intravenous.1 ENTYVIO SC is expected to be available in the U.S. as a single-dose pre-filled pen by the end of October.

Arrowhead Pharmaceuticals, Inc. announced that as an inducement to entering into employment with the Company, on September 26, 2023, the Company’s Board of Directors approved “inducement” grants to 47 new employees under Rule 5635 of the NASDAQ Listing Rules.

Elicio Therapeutics, Inc. announced promising preliminary relapse-free survival data from the ongoing Phase 1 study of its lead asset, ELI-002.

Everest Medicines, a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced that the Taiwan Food and Drug Administration has approved the New Drug Application for XERAVA® for the treatment of complicated intra-abdominal infections.

Antengene Corporation Limited announced that it will present five programs at the 2023 Society of Immunology in Cancer Annual Meeting to be held in San Diego from November 1-5, 2023.

BioCity Biopharma and AstraZeneca signed an agreement to collaborate on a Phase Ib/II clinical study to evaluate the safety and efficacy of BioCity’s BC3402, a monoclonal antibody targeting the T cell immunoglobulin and mucin domain-containing protein 3, also known as TIM-3, in combination with AstraZeneca’s anti-PD-L1 mAb IMFINZI for the treatment of advanced hepatocellular carcinoma.

Biomind Labs Inc. provides a corporate update outlining its research and development, intellectual property and clinical trials initiatives.

Sensei Biotherapeutics, Inc. today announced that the first patient has been dosed in the combination therapy arm of the Phase 1/2 clinical trial for SNS-101, a conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation).